Business
New development in cancer testing strategy
New development in cancer testing strategy.
About this update from Edx Medical Group Plc
[{"type":"text","content":"\n\n RNS Number : 1251T\nEDX Medical Group PLC\n20 June 2024\n \nThis announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.\n \n\n \n20 June 2024\n \n \nEDX Medical Group plc · EDX\n(AQSE: EDX)\n(\"EDX Medical\" or the \"Company\")\n \nNEW DEVELOPMENT IN GROUP CANCER TESTING STRATEGY\n \n \nCAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, today announces a strategic expansion of its cancer testing capability.\n \nEDX Medical is to launch comprehensive hereditary germline cancer testing products and services designed to accurately predict if family members of cancer patients are at increased risk from the disease.\nThe first test to be made available to health professionals in the UK is a pan-cancer test which achieves 99% sensitivity and identifies mutations in 70 genes known to be associated with cancers which have a strong inherited, genetic component including prostate, breast, colorectal, pancreatic and ovarian cancers in a single test.\nEDX Medical's comprehensive hereditary germline cancer testing products will enable doctors to advise family members of cancer patients on lifestyle choices and actions they can take to delay or prevent onset of the disease. Family members include grandparents, parents, children, siblings and other blood relatives.\n \nThe test will be available later this summer through private healthcare providers and via specific NHS Genetic and Genomic Testing Centres in cases where family members of cancer patients can be screened for genetic risk of cancer. In addition, EDX Medical will provide a support service for healthcare professionals with the test.\n \nProfessor Sir Chris Evans, OBE, founder of EDX Medical plc, commented: \"We are delighted to announce the launch of this test which we believe to be the highest quality hereditary cancer test available anywhere in the world. The fact ...